文献速递核素与放射性配体治疗肿瘤 PET/CT

接受放射性配体治疗的mCRPC患者中,PSA波动者与PSA持续下降者的生存获益相当

mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-07-19

这项双中心研究纳入176例接受PSMA靶向放射性配体治疗的mCRPC患者,按PSA变化分为持续升高、持续下降和波动三组。PSA波动组中位OS为18个月,与持续下降组的19个月无显著差异(HR 1.4,95%CI 0.78-2.49,P=0.20),但显著长于持续升高组的8个月(HR 0.49,95%CI 0.30-0.80,P<0.01)。作者认为治疗中短暂的肿瘤标志物波动不应导致治疗中断,尤其在无影像学进展时。

要点

  • 176例接受PSMA靶向RLT的mCRPC患者中,34.7%PSA持续升高,48.8%持续下降,16.5%出现波动。
  • PSA波动组中位OS 18个月,与持续下降组19个月无显著差异(HR 1.4,95%CI 0.78-2.49,P=0.20)。
  • PSA波动组中位OS显著长于持续升高组8个月(HR 0.49,95%CI 0.30-0.80,P<0.01)。

核心结论

  • 大多数接受RLT的患者PSA初始升高或下降后维持相应趋势。
  • PSA持续下降与生存延长相关,PSA波动者的生存获益与持续下降者相当。
  • 作者认为治疗中短暂的肿瘤标志物波动不应导致治疗中断,尤其在无影像学进展时。

研究设计与样本

  • 双中心研究,纳入176例接受PSMA靶向放射性配体治疗的mCRPC患者。
  • 在首次RLT前及后续周期入院日采集血样测定PSA,计算相对基线的变化。
  • 采用Kaplan-Meier曲线和log-rank检验比较持续升高、持续下降和波动亚组的OS。

主要发现

  • 176例中61例(34.7%)PSA持续升高,86例(48.8%)持续下降,29例(16.5%)出现波动。
  • 波动组29例中22例为初始下降后升高,7例为初始升高后下降。
  • 持续下降组中位OS 19个月 vs 持续升高组8个月(HR 0.35,95%CI 0.22-0.56,P<0.001)。
  • 波动组中位OS 18个月 vs 持续升高组8个月(HR 0.49,95%CI 0.30-0.80,P<0.01)。
  • 波动组 vs 持续下降组中位OS 18 vs 19个月(HR 1.4,95%CI 0.78-2.49,P=0.20),无显著差异。

临床怎么用

  • 作者认为,RLT治疗中短暂的肿瘤标志物波动不应导致治疗中断,尤其在无影像学进展时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In men with metastatic castration-resistant prostate cancer (mCRPC) scheduled for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), biochemical response is assessed based on repeated measurements of prostate-specific antigen (PSA) levels. We aimed to determine overall survival (OS) in patients experiencing sustained PSA increase, decrease, or fluctuations during therapy. MATERIALS AND METHODS: In this bicentric study, we included 176 mCRPC patients treated with PSMA-directed RLT. PSA levels were determined using blood samples prior to the first RLT and on the admission days for the following cycles. We calculated relative changes in PSA levels compared to baseline. Kaplan-Meier curves as well as log-rank test were used to compare OS of different subgroups, including patients with sustained PSA increase, decrease, or fluctuations (defined as change after initial decrease or increase after the first cycle). RESULTS: Sixty-one out of one hundred seventy-six (34.7%) patients showed a sustained increase and 86/176 (48.8%) a sustained decrease in PSA levels. PSA fluctuations were observed in the remaining 29/176 (16.5%). In this subgroup, 22/29 experienced initial PSA decrease followed by an increase (7/29, initial increase followed by a decrease). Median OS of patients with sustained decrease in PSA levels was significantly longer when compared to patients with sustained increase of PSA levels (19 vs. 8 months; HR 0.35, 95% CI 0.22-0.56; P < 0.001). Patients with PSA fluctuations showed a significantly longer median OS compared to patients with sustained increase of PSA levels (18 vs. 8 months; HR 0.49, 95% CI 0.30-0.80; P < 0.01), but no significant difference relative to men with sustained PSA decrease (18 vs. 19 months; HR 1.4, 95% CI 0.78-2.49; P = 0.20). In addition, in men experiencing PSA fluctuations, median OS did not differ significantly between patients with initial decrease or initial increase of tumor marker levels (16 vs. 18 months; HR 1.2, 95% CI 0.38-4.05; P = 0.68). CONCLUSION: Initial increase or decrease of PSA levels is sustained in the majority of patients undergoing RLT. Sustained PSA decrease was linked to prolonged survival and men with PSA fluctuations under treatment experienced comparable survival benefits. As such, transient tumor marker oscillations under RLT should rather not lead to treatment discontinuation, especially in the absence of radiological progression.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hartrampf PE, Bundschuh RA, Weinzierl FX, et al. mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease. Eur J Nucl Med Mol Imaging. 2022. PMID: 35852555. doi:10.1007/s00259-022-05910-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。